LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

United Therapeutics Corp

Fechado

SetorSaúde

400.72 5.52

Visão Geral

Variação de preço das ações

24h

Atual

Mín

396.58

Máximo

400.72

Indicadores-chave

By Trading Economics

Rendimento

-13M

310M

Vendas

4.2M

799M

P/E

Médio do Setor

15.794

35.733

EPS

6.63

Margem de lucro

38.755

Funcionários

1,305

EBITDA

54M

437M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+16.24% upside

Dividendos

By Dow Jones

Próximos Ganhos

29 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

4.9B

18B

Abertura anterior

395.2

Fecho anterior

400.72

Sentimento de Notícias

By Acuity

32%

68%

98 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

United Therapeutics Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de out. de 2024, 15:14 UTC

Grandes Movimentos do Mercado

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 de jan. de 2025, 10:30 UTC

Principais Notícias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparação entre Pares

Variação de preço

United Therapeutics Corp Previsão

Preço-alvo

By TipRanks

16.24% parte superior

Previsão para 12 meses

Média 465.56 USD  16.24%

Máximo 575 USD

Mínimo 295 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para United Therapeutics Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

8

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

292.345 / 309.245Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

98 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat